| Title |
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
|
|---|---|
| Published in |
Investigational New Drugs, April 2013
|
| DOI | 10.1007/s10637-013-9960-9 |
| Pubmed ID | |
| Authors |
Guru Sonpavde, Mingjun Wang, Leif E. Peterson, Helen Y. Wang, Teresa Joe, Martha P. Mims, Dov Kadmon, Michael M. Ittmann, Thomas M. Wheeler, Adrian P. Gee, Rong-Fu Wang, Teresa G. Hayes |
| Abstract |
Given the immunogenicity of NY-ESO-1 peptides in prostate cancer, a phase I clinical trial was designed to evaluate HLA class-I and class-II restricted NY-ESO-1 peptides in metastatic castration-resistant prostate cancer (mCRPC). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 52 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 6 | 11% |
| Researcher | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 5 | 9% |
| Student > Ph. D. Student | 5 | 9% |
| Other | 16 | 30% |
| Unknown | 9 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 30% |
| Unspecified | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Engineering | 3 | 6% |
| Immunology and Microbiology | 3 | 6% |
| Other | 9 | 17% |
| Unknown | 12 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2020.
All research outputs
#4,155,027
of 22,709,015 outputs
Outputs from Investigational New Drugs
#136
of 1,165 outputs
Outputs of similar age
#35,652
of 195,119 outputs
Outputs of similar age from Investigational New Drugs
#1
of 9 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,165 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,119 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them